FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3192412449> ?p ?o ?g. }

• W3192412449 endingPage "1051" @default.
• W3192412449 startingPage "1037" @default.
• W3192412449 abstract "Anti-seizure medications (ASMs) are commonly used to prevent recurring epileptic seizures, but around a third of people with epilepsy fail to achieve an adequate response. Vagus nerve stimulation (VNS) is clinically recommended for people with drug-resistant epilepsy (DRE) who are not suitable for surgery, but the cost-effectiveness of the intervention has not recently been evaluated. The study objective is to estimate costs and quality-adjusted life-years (QALYs) associated with using VNS as an adjunct to ongoing ASM therapy, compared to the strategy of using only ASMs in the treatment of people with DRE, from an English National Health Service perspective.A cohort state transition model was developed in Microsoft Excel to simulate costs and QALYs of the VNS + ASM and ASM only strategies. Patients could transition between five health states, using a 3-month cycle length. Health states were defined by an expected percentage reduction in seizure frequency, derived from randomized control trial data. Costs included the VNS device as well as its installation, setup, and removal; ASM therapy; adverse events associated with VNS (dyspnea, hoarseness, and cough); and health-state costs associated with epilepsy including hospitalizations, emergency department visits, neurologist visits, and primary care visits. A range of sensitivity analyses, including probabilistic sensitivity analysis, were run to assess the impact of parameter and structural uncertainty.In the base case, VNS + ASM had an estimated incremental cost-effectiveness ratio (ICER) of £17,771 per QALY gained compared to ASMs alone. The cost-effective ICER was driven by relative reductions in expected seizure frequency and the differences in health care resource use associated therewith. Sensitivity analyses found that the amount of resource use per epilepsy-related health state was a key driver of the cost component.VNS is expected to be a cost-effective intervention in the treatment of DRE in the English National Health Service.PLAIN LANGUAGE SUMMARYPeople with epilepsy are usually given anti-seizure medications (called ASMs) to help prevent their seizures from reoccurring. However, around a third of them will keep having seizures even with the medication; this is called drug-resistant epilepsy (DRE). Treatment options for DRE include, but are not limited to, surgical or therapeutic device-related interventions or trying alternative ASM combinations.In the English National Health Service (NHS), vagus nerve stimulation (VNS) therapy is recommended by the National Institute for Health and Care Excellence (NICE) for DRE patients who are still having seizures despite trying several different ASMs, and who cannot have brain surgery. Following NICE technical standards, we developed an economic model to test whether VNS would be a cost-effective add-on to ASM therapy. The model uses current costs for VNS therapy and takes a more nuanced approach to the longevity of the VNS device than previous research did.Results showed that adding VNS to ASMs can be a cost-effective way to treat DRE in today’s NHS in England. VNS reduces the number of seizures, which is expected to improve patients’ quality of life and cut NHS costs that would otherwise have been needed to look after patients who had a seizure (for example, emergency visits or inpatient hospital stays). Sensitivity analyses tested aspects of uncertainty in our model. These highlighted the need to further understand the relationship between seizures, their severity, and health care usage if we want to make improved cost-effectiveness analyses about DRE in the future." @default.
• W3192412449 created "2021-08-16" @default.
• W3192412449 creator A5003581985 @default.
• W3192412449 creator A5011953651 @default.
• W3192412449 creator A5027624736 @default.
• W3192412449 creator A5045033407 @default.
• W3192412449 creator A5068181203 @default.
• W3192412449 creator A5090784108 @default.
• W3192412449 creator A5091447436 @default.
• W3192412449 date "2021-01-01" @default.
• W3192412449 modified "2023-10-10" @default.
• W3192412449 title "An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England" @default.
• W3192412449 cites W1504660451 @default.
• W3192412449 cites W1574640567 @default.
• W3192412449 cites W1585774815 @default.
• W3192412449 cites W1799673024 @default.
• W3192412449 cites W1899072698 @default.
• W3192412449 cites W1920696238 @default.
• W3192412449 cites W1969783961 @default.
• W3192412449 cites W1975297201 @default.
• W3192412449 cites W1978386602 @default.
• W3192412449 cites W1980275243 @default.
• W3192412449 cites W1991097570 @default.
• W3192412449 cites W1993485358 @default.
• W3192412449 cites W1993874893 @default.
• W3192412449 cites W1998009314 @default.
• W3192412449 cites W2001101709 @default.
• W3192412449 cites W2003465714 @default.
• W3192412449 cites W2004189054 @default.
• W3192412449 cites W2004660567 @default.
• W3192412449 cites W2007391452 @default.
• W3192412449 cites W2014290441 @default.
• W3192412449 cites W2017088242 @default.
• W3192412449 cites W2022445793 @default.
• W3192412449 cites W2028701220 @default.
• W3192412449 cites W2034566648 @default.
• W3192412449 cites W2047620040 @default.
• W3192412449 cites W2053879251 @default.
• W3192412449 cites W2064152721 @default.
• W3192412449 cites W2085089024 @default.
• W3192412449 cites W2096688703 @default.
• W3192412449 cites W2097529890 @default.
• W3192412449 cites W2098647834 @default.
• W3192412449 cites W2109050661 @default.
• W3192412449 cites W2119483507 @default.
• W3192412449 cites W2120591307 @default.
• W3192412449 cites W2122317738 @default.
• W3192412449 cites W2128611498 @default.
• W3192412449 cites W2169403197 @default.
• W3192412449 cites W2169875394 @default.
• W3192412449 cites W2192749205 @default.
• W3192412449 cites W2395033601 @default.
• W3192412449 cites W2442539006 @default.
• W3192412449 cites W2520590215 @default.
• W3192412449 cites W2531859534 @default.
• W3192412449 cites W2777270043 @default.
• W3192412449 cites W2888221850 @default.
• W3192412449 cites W2896734389 @default.
• W3192412449 cites W2948649843 @default.
• W3192412449 cites W2995459561 @default.
• W3192412449 cites W3144446845 @default.
• W3192412449 cites W3147714437 @default.
• W3192412449 doi "https://doi.org/10.1080/13696998.2021.1964306" @default.
• W3192412449 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34348576" @default.
• W3192412449 hasPublicationYear "2021" @default.
• W3192412449 type Work @default.
• W3192412449 sameAs 3192412449 @default.
• W3192412449 citedByCount "8" @default.
• W3192412449 countsByYear W31924124492022 @default.
• W3192412449 countsByYear W31924124492023 @default.
• W3192412449 crossrefType "journal-article" @default.
• W3192412449 hasAuthorship W3192412449A5003581985 @default.
• W3192412449 hasAuthorship W3192412449A5011953651 @default.
• W3192412449 hasAuthorship W3192412449A5027624736 @default.
• W3192412449 hasAuthorship W3192412449A5045033407 @default.
• W3192412449 hasAuthorship W3192412449A5068181203 @default.
• W3192412449 hasAuthorship W3192412449A5090784108 @default.
• W3192412449 hasAuthorship W3192412449A5091447436 @default.
• W3192412449 hasBestOaLocation W31924124491 @default.
• W3192412449 hasConcept C118552586 @default.
• W3192412449 hasConcept C126322002 @default.
• W3192412449 hasConcept C159110408 @default.
• W3192412449 hasConcept C160735492 @default.
• W3192412449 hasConcept C162324750 @default.
• W3192412449 hasConcept C187212893 @default.
• W3192412449 hasConcept C194828623 @default.
• W3192412449 hasConcept C197934379 @default.
• W3192412449 hasConcept C24998067 @default.
• W3192412449 hasConcept C2778186239 @default.
• W3192412449 hasConcept C2779951463 @default.
• W3192412449 hasConcept C2780087125 @default.
• W3192412449 hasConcept C2780724011 @default.
• W3192412449 hasConcept C2781404750 @default.
• W3192412449 hasConcept C2910833928 @default.
• W3192412449 hasConcept C3018162438 @default.
• W3192412449 hasConcept C50522688 @default.
• W3192412449 hasConcept C71924100 @default.
• W3192412449 hasConcept C72563966 @default.

• next